顕微鏡的多発血管炎(MPA)(Microscopic Polyangiitis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Microscopic Polyangiitis (MPA) Overview 6
Therapeutics Development 7
Pipeline Products for Microscopic Polyangiitis (MPA) – Overview 7
Pipeline Products for Microscopic Polyangiitis (MPA) – Comparative Analysis 8
Microscopic Polyangiitis (MPA) – Therapeutics under Development by Companies 9
Microscopic Polyangiitis (MPA) – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Microscopic Polyangiitis (MPA) – Products under Development by Companies 13
Microscopic Polyangiitis (MPA) – Companies Involved in Therapeutics Development 14
Anthera Pharmaceuticals‚ Inc. 14
Aprogen, Inc. 15
ChemoCentryx, Inc. 16
Epirus Biopharmaceuticals, Inc. 17
Hospira, Inc. 18
Panacea Biotec Limited 19
Sandoz Inc. 20
Microscopic Polyangiitis (MPA) – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
blisibimod – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CCX-168 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
rituximab biosimilar – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
rituximab biosimilar – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
rituximab biosimilar – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rituximab biosimilar – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
rituximab biosimilar – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rituximab biosimilar – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Microscopic Polyangiitis (MPA) – Recent Pipeline Updates 41
Microscopic Polyangiitis (MPA) – Dormant Projects 47
Microscopic Polyangiitis (MPA) – Product Development Milestones 48
Featured News & Press Releases 48
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 48
Jun 03, 2014: ChemoCentryx’s CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50